Document:

Exhibit 10.2

 

THIS NOTE HAS NOT BEEN REGISTERED UNDER
THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY
NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM,
THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. 

 

_______________________________

 

BIONIK LABORATORIES CORP.

 

SECURED CONVERTIBLE PROMISSORY NOTE

 

	Principal Amount: US$[___]	Issue Date: [__], 2020

 

Bionik
Laboratories Corp., a Delaware corporation (the “Company”), for value received, hereby promises
to pay to [_____] or its permitted assigns or successors (the “Holder”), the principal amount of [_____]
Dollars (US$[___]) (the “Principal Amount”), without demand, on the Maturity Date (as hereinafter defined),
together with any accrued and unpaid interest due thereon. This Note shall bear interest at a fixed rate of 1% per month, beginning
on the Issue Date. Interest shall be computed based on a 360-day year of twelve 30-day months and shall be payable, along with
the Principal Amount, on the Maturity Date. Except as set forth in Section 3.1, payment of all principal and interest due
shall be in such coin or currency of the United States of America as shall be legal tender for the payment of public and private
debts at the time of payment.

 

This Note is a convertible
promissory note referred to in that certain Subscription Agreement dated as of the date hereof, or series of like subscription
agreements (individually or collectively, the “Subscription Agreement”), among the Company and the subscribers
named therein, pursuant to which the Company is seeking to borrow up to $7,000,000 (the “Offering”).

 

1.       Definitions.

 

1.1       Definitions.
The terms defined in this Section 1 whenever used in this Note shall have the respective meanings hereinafter specified.

 

“Change
in Control” means a merger or consolidation of the Company with or into any other entity in which the stockholders
of the Company immediately prior to the merger or consolidation do not own more than 50% of the outstanding voting power (assuming
conversion of all convertible securities and the exercise of all outstanding options and warrants) of the surviving entity or the
sale, lease, licensing, transfer or other disposition of all or substantially all the assets of the Company; provided, however,
that any new issuance of capital stock (or securities convertible or exercisable into capital stock) of the Company to one or more
third parties for the sole purpose of providing funding for the Company shall not constitute a Change in Control.

 

    	 	1	 

     

    

 

“Collateral”
shall mean and include all machinery, equipment, furniture, furnishings, tools, tooling, fixtures, and accessories, and all inventory,
accounts receivable, instruments, contract rights and other rights to receive the payment of money, patents, chattel paper, licenses,
leases and general intangibles, including all trade names and trade styles and all additions, accessions, modifications, improvements,
replacements and substitutions thereto and therefor, whether now owned or hereafter acquired or arising, and the proceeds, products
and income of any of the foregoing, including insurance proceeds.

 

“Common
Stock” means the common stock, par value $0.001 per share, of the Company.

 

“Conversion
Shares” means the Common Stock issued or issuable to the Holder pursuant to Article 3.

 

“Event
of Default” shall have the meaning set forth in Section 6.1.

 

“Holder”
or “Holders” means the person named above or any Person who shall thereafter become a recordholder of
this Note in accordance with the terms hereof.

 

“Issue
Date” means the issue date stated above.

 

“Maturity
Date” shall mean March 31, 2021.

 

“Note”
means this Convertible Note, as amended, modified or restated.

 

“Person”
means an individual, corporation, partnership, limited liability company, association, trust, joint venture, unincorporated organization
or any government, governmental department or agency or political subdivision thereof.

 

“Securities
Act” means the United States Securities Act of 1933, as amended.

 

2.       GENERAL
PROVISIONS.

 

2.1       Loss,
Theft, Destruction of Note. Upon receipt of evidence satisfactory to the Company of the loss, theft, destruction or
mutilation of this Note and, in the case of any such loss, theft or destruction, upon receipt of indemnity or security reasonably
satisfactory to the Company, or, in the case of any such mutilation, upon surrender and cancellation of this Note, the Company
will make and deliver, in lieu of such lost, stolen, destroyed or mutilated Note, a new Note of like tenor and unpaid principal
amount dated as of the date hereof. This Note shall be held and owned upon the express condition that the provisions of this Section
2.1 are exclusive with respect to the replacement of a mutilated, destroyed, lost or stolen Note and shall preclude any and
all other rights and remedies notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to
the replacement of negotiable instruments or other securities without their surrender.

 

2.2       Prepayment;
Redemption. This Note may not be prepaid by the Company in whole or in part, except with the prior written consent of
the Holder. This Note may not be redeemed by the Company in whole or in part, except with the prior written consent of the Holder.

 

    	 	2	 

     

    

 

3.       CONVERSION
OF NOTE.

 

3.1       Conversion.

 

(a)       Conversion
upon Maturity Date. On the Maturity Date without any action on the part of the Holder, the outstanding principal and accrued
and unpaid interest under the Notes will be converted into shares of Common Stock at a conversion price of US$9.50 per share (the
 “Conversion Price”).

 

(b)       Conversion
upon Change of Control. If a Change of Control transaction occurs prior to the Maturity Date, the outstanding principal and
accrued and unpaid interest under the Note would, at the election of the holders of a majority of the outstanding principal of
the Notes, be either (i) payable upon demand as of the closing of such Change of Control transaction or (ii) convertible into shares
of the Common Stock immediately prior to such Change of Control transaction at a price per share equal to the lesser of (x) the
Conversion Price, or (y) the per share consideration to be received by the holders of the Common Stock in such Change of Control
transaction.

 

(c)       Cancellation.
Upon and as of the Maturity Date, this Note will be cancelled on the books and records of the Company and shall solely represent
the right to receive the Conversion Shares.

 

3.2       Delivery
of Securities Upon Conversion.

 

(a)       As
soon as is practicable after the Maturity Date or an event pursuant to Section 3.1(b)(ii), the Company shall deliver to the Holder
a certificate or certificates evidencing the Conversion Shares issuable to the Holder.

 

(b)       The
issuance of certificates for Conversion Shares upon conversion of this Note shall be made without charge to the Holder for any
issuance tax in respect thereof or other cost incurred by the Company in connection with such conversion and the related issuance
of securities. Upon conversion of this Note, the Company shall take all such actions as are necessary in order to ensure that the
Conversion Shares so issued upon such conversion shall be validly issued, fully paid and nonassessable.

 

3.3       Fractional
Shares. No fractional shares or scrip representing fractional shares shall be issued upon conversion of this Note. If
any conversion of this Note would create a fractional share or a right to acquire a fractional share, the Company shall round to
the nearest whole number.

 

3.4       Anti-Dilution. 
In the event this Note converts into Common Stock pursuant to Section 3.1(a) and the Company raises capital through the sale of
Common Stock (“New Capital Stock Raise”) for cash during the period ending on the three (3) year anniversary
of the conversion date of the Related Notes (for the avoidance of doubt, including this Note), and the price per share of the shares
sold in the New Capital Stock Raise (the “Offering Price”) minus 20% is less than the Conversion Price,
then in such event the Company shall issue to the Holder, at no further cost to the Holder, additional shares of Common Stock equal
to the number of Conversion Shares the Holder would have received upon conversion if the Conversion Price was a price equal to
a 20% discount to the Offering Price, less the number of shares of Conversion Shares actually issued on or as of the Maturity Date.

 

    	 	3	 

     

    

 

4.       COLLATERAL.

 

4.1       Security
Interest In The Collateral.  To secure the prompt payment and performance to Holder of the obligations hereunder,
the Company hereby assigns, pledges and grants to Holder a continuing security interest in and to, and lien on, all of its Collateral.

 

4.2       Perfection
Of Security Interest.  The Company shall take all action that may be necessary or desirable, or that Holder may
request, so as at all times to maintain the validity, perfection, enforceability and priority of Holder’s security interest
in and lien on the Collateral or to enable Holder to protect, exercise or enforce its rights hereunder and in the Collateral. 
By its signature hereto, the Company hereby authorizes Holder to file against the Company one or more financing, continuation or
amendment statements pursuant to the Uniform Commercial Code in form and substance reasonably satisfactory to Holder.

 

5.       STATUS;
RESTRICTIONS ON TRANSFER.

 

5.1       Status
of Note. This Note is a direct, general and unconditional obligation of the Company, and constitutes a valid and legally
binding obligation of the Company, enforceable in accordance with its terms subject, as to enforcement, to bankruptcy, insolvency,
reorganization and other similar laws of general applicability relating to or affecting creditors’ rights and to general
principles of equity. This Note does not confer upon the Holder any right to vote or to consent or to receive notice as a stockholder
of the Company, as such, in respect of any matters whatsoever, or any other rights or liabilities as a stockholder, prior to conversion
hereof into Conversion Shares.

 

5.2       Restrictions
on Transferability. This Note and any Conversion Shares issued with respect to this Note, have not been registered under
the Securities Act, or under any state securities or so-called “blue sky laws,” and may not be offered, sold, transferred,
hypothecated or otherwise assigned except (a) pursuant to a registration statement with respect to such securities which is effective
under the Act or (b) upon receipt from counsel satisfactory to the Company of an opinion, which opinion is satisfactory in form
and substance to the Company, to the effect that such securities may be offered, sold, transferred, hypothecated or otherwise assigned
(i) pursuant to an available exemption from registration under the Act and (ii) in accordance with all applicable state securities
and so-called “blue sky laws.” The Holder agrees to be bound by such restrictions on transfer. The Holder further consents
that the certificates representing the Conversion Shares that may be issued with respect to this Note may bear a restrictive legend
to such effect.

 

5.3       COVENANTS.
In addition to the other covenants and agreements of the Company set forth in this Note, the Company covenants and agrees that
so long as this Note shall be outstanding, if any one or more events occur which constitute or which, with the giving of notice
or the lapse of time or both, would constitute an Event of Default or if the Holder shall demand payment or take any other action
permitted upon the occurrence of any such Event of Default, the Company will forthwith give notice to the Holder, specifying the
nature and status of the Event of Default or other event or of such demand or action, as the case may be.

 

    	 	4	 

     

    

 

6.       REMEDIES.

 

6.1       Events
of Default. “Event of Default” wherever used herein means any one of the following events:

 

(a)       The
Company shall fail to issue and deliver the Conversion Shares in accordance with Section 3;

 

(b)       Default
in the due and punctual payment of the principal of, or any other amount owing in respect of (including interest), this Note when
and as the same shall become due and payable;

 

(c)       Default
in the performance or observance of any covenant or agreement of the Company in this Note (other than a covenant or agreement a
default in the performance of which is specifically provided for elsewhere in this Section 6.1), and the continuance of
such default for a period of 10 days after there has been given to the Company by the Holder a written notice specifying such default
and requiring it to be remedied;

 

(d)       The
entry of a decree or order by a court having jurisdiction adjudging the Company as bankrupt or insolvent; or approving as properly
filed a petition seeking reorganization, arrangement, adjustment or composition of or in respect of the Company under the Federal
Bankruptcy Code or any other applicable federal or state law, or appointing a receiver, liquidator, assignee, trustee or sequestrator
(or other similar official) of the Company or of any substantial part of its property, or ordering the winding-up or liquidation
of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 calendar days;

 

(e)       The
institution by the Company of proceedings to be adjudicated as bankrupt or insolvent, or the consent by it to the institution of
bankruptcy or insolvency proceedings against it, or the filing by it of a petition or answer or consent seeking reorganization
or relief under the Federal Bankruptcy Code or any other applicable federal or state law, or the consent by it to the filing of
any such petition or to the appointment of a receiver, liquidator, assignee, trustee or sequestrator (or other similar official)
of the Company or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors;

 

(f)       The
Company seeks the appointment of a statutory manager or proposes in writing or makes a general assignment or an arrangement or
composition with or for the benefit of its creditors or any group or class thereof or files a petition for suspension of payments
or other relief of debtors or a moratorium or statutory management is agreed or declared in respect of or affecting all or any
material part of the indebtedness of the Company; or

 

(g)       It
becomes unlawful for the Company to perform or comply with its obligations under this Note.

 

6.2       Effects
of Default. If an Event of Default occurs and is continuing, then and in every such case the Holder may declare this
Note to be due and payable immediately, by a notice in writing to the Company, and upon any such declaration, the Company shall
pay to the Holder the outstanding principal amount of this Note plus all accrued and unpaid interest through the date the Note
is paid in full. Holder shall further have the right to exercise any and all rights and remedies provided for herein, under the
Uniform Commercial Code and at law or equity generally, including the right to foreclose the security interests granted herein
and to realize upon any Collateral by any available judicial procedure and/or to take possession of and sell any or all of the
Collateral with or without judicial process. Holder may enter the Company’s premises without legal process and without incurring
liability to the Company therefor, and Holder may thereupon, or at any time thereafter, in its discretion without notice or demand,
take the Collateral and remove the same to such place as Holder may deem advisable and Holder may require the Company to make the
Collateral available to Holder at a convenient place.

 

    	 	5	 

     

    

 

6.3       Remedies
Not Waived; Exercise of Remedies. No course of dealing between the Company and the Holder or any delay in exercising
any rights hereunder shall operate as a waiver by the Holder. No failure or delay by the Holder in exercising any right, power
or privilege under this Note shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other
or further exercise thereof or the exercise of any other right, power or privilege. By acceptance hereof, the Holder acknowledges
and agrees that this Note is one of a series of Convertible Promissory Notes of similar tenor issued by the Company pursuant to
the Offering (collectively, the “Related Notes”) and that upon the occurrence and during the continuance
of any Event of Default, the holders of a majority in original principal amount of the Related Notes, including this Note, shall
have the right to act on behalf of the holders of all such Notes in exercising and enforcing all rights and remedies available
to all of such holders under this Note, including, without limitation, foreclosure of any judgment lien on any assets of the Company.
By acceptance hereof, the Holder agrees not to independently exercise any such right or remedy without the consent of the holders
of a majority in original principal amount of the Related Notes (for the avoidance of doubt, including this Note).

 

7.       MISCELLANEOUS.

 

7.1       Severability.
If any provision of this Note shall be held to be invalid or unenforceable, in whole or in part, neither the validity nor the enforceability
of the remainder hereof shall in any way be affected.

 

7.2       Notice.
Where this Note provides for notice of any event, such notice shall be given (unless otherwise herein expressly provided) in writing
and either (a) delivered personally, (b) sent by certified, registered or express mail, postage prepaid or (c) sent by facsimile
or other electronic transmission, and shall be deemed given when so delivered personally, sent by facsimile or other electronic
transmission (confirmed in writing) or mailed. Notices shall be addressed, if to Holder, to its address as provided in the Subscription
Agreement or, if to the Company, to its principal office.

 

7.3       Governing
Law. This Note shall be governed by, and construed in accordance with, the laws of the State of Delaware (without giving
effect to any conflicts or choice of law provisions that would cause the application of the domestic substantive laws of any other
jurisdiction).

 

    	 	6	 

     

    

 

7.4       Forum.
The Holder and the Company hereby agree that any dispute which may arise out of or in connection with this Note shall be adjudicated
before a court of competent jurisdiction in the State of Delaware and they hereby submit to the exclusive jurisdiction of the courts
of the State of Delaware, as well as to the jurisdiction of all courts to which an appeal may be taken from such courts, with respect
to any action or legal proceeding commenced by either of them and hereby irrevocably waive any objection they now or hereafter
may have respecting the venue of any such action or proceeding brought in such a court or respecting the fact that such court is
an inconvenient forum.

 

7.5       Headings.
The headings of the Articles and Sections of this Note are inserted for convenience only and do not constitute a part of this Note.

 

7.6       Amendments.
This Note may be amended or waived only with the written consent of the Company and the holders of a majority in original aggregate
principal amount of this Note and the other Related Notes. Any such amendment or waiver shall be binding on all holders of the
Notes, even if they do not execute such consent, amendment or waiver.

 

7.7       No
Recourse Against Others. The obligations of the Company under this Note are solely obligations of the Company and no
officer, employee or stockholder shall be liable for any failure by the Company to pay amounts on this Note when due or perform
any other obligation.

 

7.8       Assignment;
Binding Effect. This Note may be assigned by the Company without the prior written consent of the Holder. This Note
shall be binding upon and inure to the benefit of both parties hereto and their respective permitted successors and assigns.

 

Signature
on the Following Page

 

 

 

    	 	7	 

     

    

 

In
Witness Whereof, the Company has caused this Note to be signed by its duly authorized officer on the date hereinabove
written.

 

	 	Bionik Laboratories Corp.

	 	 	 	 
	 	By:	   	 	 
	 	Name:	Eric Dusseux	 
	 	Title:	CEO	 

 

 

 

 

 

 

 

 

 

 

 

 

 

Signature
Page to Convertible Promissory NoteExhibit 10.3

 

ALLONGE #2 TO CONVERTIBLE PROMISSORY
NOTE

 

Allonge #2 (this “Allonge”)
to that certain Convertible Promissory Note dated September 26, 2019, as amended by that Allonge #1 dated as of March 30, 2020
(as so amended, the “Convertible Promissory Note”) attached hereto as Exhibit 1 and made a part hereof in the
principal amount of $70,000, from Bionik Laboratories Corp., as Maker (“Maker”), to Celeste Management, as Holder (“Holder”).

 

 

Maker and Holder agree
that the Convertible Promissory Note shall be further amended and revised as follows:

 

1.       The
paragraph immediately prior to Article 1 of the Convertible Promissory Note shall be amended and replaced as follows:

 

“This Note is a convertible promissory
note referred to in that certain Subscription Agreement dated as of the date hereof, or series of like subscription agreements
(individually or collectively, the “Subscription Agreement”), among the Company and the subscribers named
therein, pursuant to which the Company is seeking to borrow up to $7,000,000 (as amended from $3,000,000 or up to $7,000,000 if
oversubscribed) (the “Offering”).”

 

2.       The
definition of “Maturity Date” in Section 1.1 of the Convertible Promissory Note shall be amended and replaced to read
as follows:

 

““Maturity
Date” shall mean March 31, 2021.”

 

3.       The
definition of “Qualified Financing” in Section 1.1 of the Convertible Promissory Note shall be deleted in its entirety.

 

4.       Section
3.4 of the Convertible Promissory Note shall be amended and replaced to read as follows:

 

“Anti-Dilution. 
In the event this Note converts into Common Stock pursuant to Section 3.1(a) and the Company raises capital through the sale of
Common Stock (“New Capital Stock Raise”) for cash during the period ending on the three (3) year anniversary
of the conversion date of the Related Notes (for the avoidance of doubt, including this Note), and the price per share of the shares
sold in the New Capital Stock Raise (the “Offering Price”) minus 20% is less than the Conversion Price,
then in such event the Company shall issue to the Holder, at no further cost to the Holder, additional shares of Common Stock equal
to the number of Conversion Shares the Holder would have received upon conversion if the Conversion Price was a price equal to
a 20% discount to the Offering Price, less the number of shares of Conversion Shares actually issued on or as of the Maturity Date.”

 

    	 	 	 

     

    

 

Except as
expressly reflected herein, the Convertible Promissory Note will remain in full force and effect. This Allonge is intended to be
attached to and made a permanent part of the Convertible Promissory Note.

 

Dated as of the 2nd
day of June 2020.

 

 

	Maker:	BIONIK LABORATORIES CORP.	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Eric Dusseux	 
	 	Name:	Eric Dusseux	 
	 	Title:	CEO	 
	 	 	 	 
	Holder:	CELESTE MANAGEMENT	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Dimitri Boulanger	 
	 	Name:	Dimitri Boulanger	 
	 	Title:	CEO	 

 

 

 

 

 

 

 

    	 	2	 

     

    

 

EXHIBIT A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]